Be a Smart Investor
Tuesday, October 3, 2017
Seres Therapeutics Inc. (MCRB) Tumbled To A 2-Month Low On Study Results
Seres Therapeutics Inc. (MCRB) reported results from its Phase 1b study of SER-287 in patients with mild-to-moderate Ulcerative Colitis.
from RTT - Before the Bell http://ift.tt/2fNdX6B
via
IFTTT
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment